Improving immune responses to HIV-1 through new nanoparticle adjuvants
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
This study is testing new tiny particles that could help boost the immune system's response to HIV-1, aiming to create better vaccines that help your body make strong and lasting antibodies against the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10657401 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticulate adjuvants to enhance the immune response against HIV-1. By using biodegradable synthetic polymer nanoparticles, the study aims to improve the quality and persistence of antibody responses specific to the HIV-1 envelope protein. The approach involves evaluating the effectiveness of these adjuvants in stimulating immune cells, particularly B cells, to produce long-lasting antibodies that can neutralize the virus. Patients may benefit from advancements in vaccine development that could lead to more effective HIV-1 vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for HIV-1 infection who may benefit from improved vaccination strategies.
Not a fit: Patients who are already HIV-positive or those who have contraindications to vaccination may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV-1 vaccine that generates stronger and longer-lasting immune responses.
How similar studies have performed: Previous studies have shown promise with nanoparticulate adjuvants in enhancing immune responses, indicating potential for success in this novel approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Kasturi, Sudhir Pai — Emory University
- Study coordinator: Kasturi, Sudhir Pai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.